Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06134960 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jun 30, 2026 → Jun 30, 2027
See other at-risk trials from Peking University

Record History

  1. Primary completion pushed from Jun 30, 2026 to Jun 30, 2027v2 Show 4 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Nov 16, 2023 to Nov 16, 2024
    • Study completion pushed from Nov 15, 2026 to Nov 15, 2027
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Peking University
118 trials monitored
See 4 trials at risk
Pancreatic Cancer
1,739 trials monitored
See 106 trials at risk
Gastric Cancer
1,278 trials monitored
See 63 trials at risk
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.
Trial Details
NCT Number NCT06134960
Lead Sponsor Peking University
Collaborators: KAEDI
Conditions
(from sponsor)		 Gastric Cancer, Pancreatic Cancer, Solid Tumor
Related terms Pancreatic Neoplasms, Stomach Neoplasms
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov